Table 3.
Univariate and multivariable analyses for factors associated with survival (N = 107 106)*
| Characteristic | No. (%) | Unadjusted HR† (95% CI) | Adjusted HR*,† (95% CI) |
| CPM | |||
| CPM not performed | 98 204 (91.69) | 1 (referent) | 1 (referent) |
| CPM performed | 8902 (8.31) | 0.63 (0.57 to 0.69) | 0.84 (0.76 to 0.92) |
| Age, y | |||
| 18–49 | 27 336 (25.52) | 1 (referent) | 1 (referent) |
| 50–59 | 24 880 (23.23) | 0.85 (0.80 to 0.90) | 1.00 (0.94 to 1.05)‡ |
| 60–90 | 54 890 (51.25) | 0.92 (0.88 to 0.96§ | 1.35 (1.28 to 1.41) |
| Race and/or ethnicity | |||
| Non-Hispanic white | 79 992 (74.68) | 1 (referent) | 1 (referent) |
| Hispanic white | 8680 (8.10) | 1.35 (1.26 to 1.45) | 1.01 (0.94 to 1.09)‖ |
| Black | 9238 (8.63) | 2.03 (1.92 to 2.15) | 1.44 (1.36 to 1.53) |
| Asian or Pacific Islander | 8813 (8.23) | 0.82 (0.76 to 0.89) | 0.87 (0.78 to 0.92) |
| Other unspecified or unknown | 383 (0.36) | 0.32 (0.17 to 0.59) | 0.37 (0.20 to 0.70)§ |
| AJCC 5th cancer stage | |||
| 0 | 14 547 (13.58) | 1 (referent) | 1 (referent) |
| I | 34 581 (32.29) | 3.33 (2.78 to 3.99) | 8.97 (7.39 to 10.89) |
| IIA | 26 886 (25.10) | 8.80 (7.38 to 10.50) | 19.06 (15.75 to 23.07) |
| IIB | 19 417 (18.13) | 19.20 (16.12 to 22.85) | 32.22 (26.55 to 39.09) |
| IIIA | 6368 (5.95) | 33.14 (27.75 to 39.59) | 45.94 (37.71 to 55.96) |
| IIIB | 5307 (4.95) | 59.86 (50.19 to 71.40) | 74.49 (61.47 to 90.28) |
| Lymph node status | |||
| Negative | 55 979 (52.27) | 1 (referent) | 1 (referent) |
| 1–3 positive lymph nodes | 23 309 (21.76) | 2.90 (2.74 to 3.07) | 1.19 (1.11 to 1.27) |
| ≥4 positive lymph nodes | 16 225 (15.15) | 7.86 (7.46 to 8.28) | 2.40 (2.24 to 2.57) |
| Unknown | 11 593 (10.82) | 1.88 (1.73 to 2.03) | 2.31 (2.12 to 2.52) |
| Tumor grade | |||
| 1 | 14 168 (13.23) | 1 (referent) | 1 (referent) |
| 2 | 39 267 (36.66) | 2.37 (2.13 to 2.65) | 1.59 (1.43 to 1.78) |
| 3 | 37 342 (34.86) | 6.56 (5.90 to 7.29) | 2.61 (2.34 to 2.91) |
| 4 | 4505 (4.21) | 3.30 (2.86 to 3.81) | 2.86 (2.47 to 3.31) |
| Unknown | 11 824 (11.04) | 2.09 (1.84 to 2.38) | 1.66 (1.46 to 1.89) |
| ER status | |||
| Positive | 61 002 (56.95) | 1 (referent) | 1 (referent) |
| Negative | 19 149 (17.88) | 3.38 (3.23 to 3.53) | 2.36 (2.25 to 2.48) |
| Unknown or not done | 26 955 (25.17) | 0.90 (0.85 to 0.95) | 1.49 (1.40 to 1.58) |
| Histology type | |||
| Nonlobular | 86 405 (80.67) | 1 (referent) | 1 (referent) |
| Lobular | 20 701 (19.33) | 0.73 (0.69 to 0.78) | 0.86 (0.81 to 0.92) |
| First tumor diagnosis | |||
| No | 28 671 (26.77) | 1 (referent) | 1 (referent) |
| Yes | 78 435 (73.23) | 1.56 (1.48 to 1.64) | 0.59 (0.56 to 0.63) |
*
Adjusted for all other variables shown in the table. Stage according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 5th edition. All P values were calculated using Cox regression with the Wald test for significance. All P values were two-sided. CI = confidence interval; CPM = contralateral prophylactic mastectomy; ER = estrogen receptor.
†
All P values were less than .001.
‡
P = .97.
§
P < .01
‖
P = .61.